# Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection

> **NCT02859961** · PHASE2,PHASE3 · COMPLETED · sponsor: **CytoDyn, Inc.** · enrollment: 562 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** PRO 140 (350 mg)
- **DRUG:** PRO 140 (525 mg)
- **DRUG:** PRO 140 (700 mg)

## Key facts

- **NCT ID:** NCT02859961
- **Lead sponsor:** CytoDyn, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-07
- **Primary completion:** 2020-09-16
- **Final completion:** 2020-12-07
- **Target enrollment:** 562 (ACTUAL)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02859961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02859961, "Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT02859961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*